Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Legacy Health System
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Over 18 years of age
ER Negative and PR Negative
Progression of disease in the metastatic setting despite taxane or other chemotherapeutic therapies including Herceptin (patients on Herceptin may continue this therapy while on study)
Maximized chemotherapy in the metastatic setting or patient experienced side effects contributing to decreased quality of life and elects to defer chemotherapy
Evaluable disease by either:
* CT Scan with or without contrast (lesions must be greater than 2 mm)
* PET Scan, or Bone Scan, or Plain skeletal films
* Chest wall or skin recurrence (digital photo to capture evaluable disease)
Evaluable symptoms (pain, shortness of breath, fatigue, anorexia)
Performance Status of 0, 1, or 2
Bilateral mammogram performed within one year before registration
You may not be if
Uncontrolled hypercalcemia greater than 11
Uncontrolled congestive heart failure greater than 2 NYHA class
Central Nervous System metastasis
Concomitant steroid use
Performance Status of greater than 2
Bilirubin greater than 5.5
Clareo Health | Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer
